Flu vaccine provider Seqirus is to develop a £15.3m production facility at its manufacturing plant in Liverpool as part of a planned expansion of activity at the site.
You must be logged in to continue
Register for free to finish this article.
Sign up now for the following benefits:
To access this article REGISTER NOW
Would you like print copies, app and digital replica access too? SUBSCRIBE for as little as £6 per week.